<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03301506</url>
  </required_header>
  <id_info>
    <org_study_id>CB8025-31731</org_study_id>
    <nct_id>NCT03301506</nct_id>
  </id_info>
  <brief_title>Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)</brief_title>
  <official_title>An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CymaBay Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CymaBay Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in
      Subjects with Primary Biliary Cholangitis (PBC)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary:

      To evaluate the long-term safety and tolerability of seladelpar

      Secondary:

      To evaluate the long-term efficacy of seladelpar
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    unexpected histological findings in a phase 2 study in NASH patients CB8025-21730
  </why_stopped>
  <start_date type="Actual">December 12, 2017</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events (AE) and Treatment Emergent Adverse Events (TEAEs), Biochemistry and Hematology and NCI CTCAE Version 4.0</measure>
    <time_frame>Through study completion, up to 60 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Laboratory Value: Serum Alkaline Phosphatase (AP)</measure>
    <time_frame>Through study completion, up to 60 Months</time_frame>
    <description>Serum Alkaline Phosphatase (AP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Value: Aspartate Aminotransferase (AST)</measure>
    <time_frame>Through study completion, up to 60 Months</time_frame>
    <description>Aspartate Aminotransferase (AST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Value: Alanine Aminotransferase (ALT)</measure>
    <time_frame>Through study completion, up to 60 Months</time_frame>
    <description>Alanine Aminotransferase (ALT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Value: Gamma-glutamyl Transferase (GGT)</measure>
    <time_frame>Through study completion, up to 60 Months</time_frame>
    <description>Gamma-glutamyl Transferase (GGT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Value: 5'nucleotidase</measure>
    <time_frame>Through study completion, up to 60 Months</time_frame>
    <description>5'nucleotidase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Value: Bilirubin - Total Bilirubin</measure>
    <time_frame>Through study completion, up to 60 Months</time_frame>
    <description>Bilirubin - Total Bilirubin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Value: Bilirubin - Conjugated Bilirubin</measure>
    <time_frame>Through study completion, up to 60 Months</time_frame>
    <description>Bilirubin - Conjugated Bilirubin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Value: Bilirubin - Unconjugated Bilirubin</measure>
    <time_frame>Through study completion, up to 60 Months</time_frame>
    <description>Bilirubin - Unconjugated Bilirubin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Value: Bone Specific Alkaline Phosphatase (AP)</measure>
    <time_frame>Through study completion, up to 60 Months</time_frame>
    <description>Bone Specific Alkaline Phosphatase (AP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Value: Triglycerides (TG)</measure>
    <time_frame>Through study completion, up to 60 Months</time_frame>
    <description>Triglycerides (TG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Value: Total Cholesterol (TC)</measure>
    <time_frame>Through study completion, up to 60 Months</time_frame>
    <description>Total Cholesterol (TC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Value: High Density Lipoprotein Cholesterol (HDL-C)</measure>
    <time_frame>Through study completion, up to 60 Months</time_frame>
    <description>High Density Lipoprotein Cholesterol (HDL-C)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Value: Low Density Lipoprotein Cholesterol (LDL-C)</measure>
    <time_frame>Through study completion, up to 60 Months</time_frame>
    <description>Low Density Lipoprotein Cholesterol (LDL-C)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">356</enrollment>
  <condition>Primary Biliary Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Seladelpar 2 mg Capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Seladelpar 5 mg Capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Seladelpar 10 mg Capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Seladelpar 2 mg Capsule</intervention_name>
    <description>Subjects will be assigned to a treatment group based on the seladelpar dose received at End of Treatment in a previous PBC study with seladelpar.</description>
    <arm_group_label>Seladelpar 2 mg Capsule</arm_group_label>
    <other_name>MBX-8025</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Seladelpar 5 mg Capsule</intervention_name>
    <description>Subjects will be assigned to a treatment group based on the seladelpar dose received at End of Treatment in a previous PBC study with seladelpar.</description>
    <arm_group_label>Seladelpar 5 mg Capsules</arm_group_label>
    <other_name>MBX-8025</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Seladelpar 10 mg Capsule</intervention_name>
    <description>Subjects will be assigned to a treatment group based on the seladelpar dose received at End of Treatment in a previous PBC study with seladelpar.</description>
    <arm_group_label>Seladelpar 10 mg Capsule</arm_group_label>
    <other_name>MBX-8025</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Must have given written informed consent (signed and dated) and any authorizations
             required by local law

          2. Participated in a PBC study with seladelpar

          3. Females of reproductive potential must use at least one barrier contraceptive and a
             second effective birth control method during the study and for at least 90 days after
             the last dose. Male subjects who are sexually active with female partners of
             reproductive potential must use barrier contraception and their female partners must
             use a second effective birth control method during the study and for at least 90 days
             after the last dose

        Exclusion Criteria:

        Exclusion criteria are applicable only for subjects with study drug interruption greater
        than four weeks prior to Day 1 of this study.

          1. Treatment-related adverse event leading to study drug discontinuation in a previous
             PBC study with seladelpar (MBX-8025)

          2. A medical condition, other than PBC, that in the investigator's opinion would preclude
             full participation in the study or confound its results (e.g., cancer)

          3. AST or ALT above 3 × ULN

          4. Total bilirubin above 2.0 mg/dL

          5. Creatine kinase above 2.5 × ULN

          6. Serum creatinine above 1.5 × ULN

          7. Auto-immune hepatitis

          8. Primary sclerosing cholangitis

          9. Known history of alpha-1-antitrypsin deficiency

         10. Known history of chronic viral hepatitis

         11. For females, pregnancy or breast-feeding

         12. Use of colchicine, methotrexate, azathioprine, or systemic steroids within two months
             prior to screening

         13. Current use of fibrates or simvastatin

         14. Current use of obeticholic acid

         15. Use of an experimental or unapproved treatment for PBC

         16. Use of experimental or unapproved immunosuppressant

         17. Any other condition(s) that would compromise the safety of the subject or compromise
             the quality of the clinical study, as judged by the Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Southern California Liver &amp; GI Center</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Healthcare</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schiff Center for Liver Disease</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive Healthcare of Georgia</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Novi</city>
        <state>Michigan</state>
        <zip>48377</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Therapy and Advanced Research LLC (STAR)</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwell Health Center for Liver Disease and Transplantation</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai - The Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Clinical Reearch Center, LLC</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.T. Southwestern Medical Center Investigation Drug Services</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinnacle Clinical Research</name>
      <address>
        <city>Live Oak</city>
        <state>Texas</state>
        <zip>78233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maryview Hospital Inc.</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary Liver Unit</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite - Universitatsmedizin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ifi-Studien und Projeckte GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsmedizin</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinik</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Newcastle upon Tyne Hospitals NHS Foundation Trust</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <state>Northumberland</state>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hull and East Yoskshire Hospital NHS Trust</name>
      <address>
        <city>Hull</city>
        <zip>HU3 2JZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free London NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Plymouth Hospital</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portsmouth Hospital NHS Trust</name>
      <address>
        <city>Portsmouth</city>
        <zip>PO6 3LY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>September 26, 2017</study_first_submitted>
  <study_first_submitted_qc>September 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2017</study_first_posted>
  <last_update_submitted>December 9, 2019</last_update_submitted>
  <last_update_submitted_qc>December 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PBC</keyword>
  <keyword>Primary Biliary Cholangitis (PBC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

